A clinical-stage oncology company building the first AAV gene therapy designed to be made once and used across many cancers.
Visit site ›What they do
Siren’s platform, Universal AAV Immuno-Gene Therapy, fuses two modalities that have historically been developed separately: AAV gene therapy and cytokine immunotherapy. A vectorized cytokine is infused directly into the tumor, where it does four things at once: kills tumor cells through endogenous cytokine expression, activates macrophages, recruits natural killer cells, and draws in cytotoxic T lymphocytes against both tumor and AAV antigens.
Source: Company launch releaseKey facts
What makes them different
Most gene therapies are built for one indication and one patient population. Siren’s claim is universality: a single off-the-shelf therapeutic, delivered locally rather than systemically, that applies across solid tumors. The company frames it as reimagining solid tumor treatment rather than improving on it.
Why KMAK invested
Gene therapy has spent two decades solving for rare disease, one indication at a time, at a cost structure that never scales. Siren inverts that. A single construct that works across solid tumors changes the economics of the whole category, not just the outcome for one patient group. We backed a founder who spent her academic career inside AAV biology and left to build the thing she knew was missing, alongside investors who take that kind of bet seriously. Glioma is the hardest possible proving ground, which is exactly why an IND clearance there matters.